Reanalysis of the Women's Health Initiative oral contraceptive data reveals no evidence of delayed cardiovascular benefit.
Stefanick, Marcia L; Prentice, Ross L; Anderson, Garnet; Gass, Margery; Manson, JoAnn E; Hendrix, Susan L; Vista-Deck, Diane; McNeeley, Gene.
; 83(4): 853-4, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15820789
Oral contraceptives versus physical exercise on cardiovascular and metabolic risk factors in women with polycystic ovary syndrome: a randomized controlled trial.
Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence: a systematic review and meta-analysis.
Contraception options for patients with known hereditary risk for ovarian cancer.
The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment.
Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens?
Preventive therapy for cancer.
Compliance with pregnancy prevention measures during isotretinoin therapy.
"The pill" and rheumatoid arthritis: benefits for the future?
The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytic epidemiological studies using meta-analysis.
Oral contraceptives come of age.